{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027132","form_type":"8-K","ticker":"CELU","cik":"0001752828","company_name":"Celularity Inc","filed_at":"2026-06-03T21:22:06+00:00","discovered_at":"2026-06-03T21:24:00.304063+00:00","generated_at":"2026-06-03T21:24:26.129698+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Celularity names Rick Gonzalez Chief Commercial Officer, advances longevity and cenplacel-L focus","bullets":["Rick Gonzalez appointed CCO effective May 29, 2026, reporting to Chairman & CEO Robert Hariri.","Gonzalez has 20+ years biotech experience; previously CCO at Alume Biosciences, CEO at Navidea.","Company sharpens focus on longevity, regenerative medicine; cenplacel-L sees physician demand in Florida.","Out-licensed biomaterials to NexGel for up to $30M, reducing liabilities by ~$13M (previously announced)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027132","json":"https://secwatch.observer/filing/0001493152-26-027132.json","markdown":"https://secwatch.observer/filing/0001493152-26-027132.md","text":"https://secwatch.observer/filing/0001493152-26-027132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/0001493152-26-027132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:24:26.129698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d20774bf51","claim":"Rick Gonzalez was appointed as Chief Commercial Officer at Celularity Inc.","evidence_excerpt":"On May 29, 2026, Celularity Inc. (“Celularity”) appointed Rick Gonzalez as Chief Commercial Officer of Celularity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/0001493152-26-027132-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}